Title:
HER2 S310F SPECIFIC ANTIGEN-BINDING MOLECULES
Document Type and Number:
WIPO Patent Application WO/2020/095866
Kind Code:
A1
Abstract:
An objective of the present invention is to provide antigen-binding molecules that specifically bind to HER2 mutant. The present invention provides antigen-binding molecules that specifically bind to HER2 mutant, and are capable of modulating and/or activating an immune response; compositions comprising the antigen-binding molecule; and methods of using the same.
Inventors:
KODAMA TATSUSHI (SG)
SUN YANG (SG)
SUN YANG (SG)
Application Number:
PCT/JP2019/043179
Publication Date:
May 14, 2020
Filing Date:
November 05, 2019
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
International Classes:
C07K16/32; C12N15/13; C12P21/08
Domestic Patent References:
| WO2009099829A1 | 2009-08-13 |
Foreign References:
| US9610298B1 | 2017-04-04 |
Other References:
ENDO, Y. ET AL.: "HER2 mutation status in Japanese HER2-positive breast cancer patients.", BREAST CANCER, vol. 23, 2016, pages 902 - 907, XP036085682, DOI: 10.1007/s12282-015-0659-y
See also references of EP 3877420A4
See also references of EP 3877420A4
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF: